Farmacore Biotechnology Ltd

farmacore.com.be

Farmcore is a biotech company that develops and improves value in innovative biotechnological products during all stages, since conception of projects, to supply of active pharmaceutical ingredients (immunobiologicals) specially for the veterinary sector. As a Contract Manufacturing Organization, Farmcore owns technologically advanced Bioprocess Facilities allowing the production of a wide range of plasmid needs, permitting the lowest cost of production and highest product quality, especially in GMP regulated environments.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ENZO BIOCHEM’S FULL SERVICE CLINICAL LABORATORY TO LAUNCH CORONAVIRUS (COVID-19) TESTING SERVICES NEXT WEEK

Biotechnology news | March 06, 2020

news image

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection...

Read More

MEDICAL

EMMAUS LIFE SCIENCES ANNOUNCES LAUNCH OF FULL-SERVICE TELEHEALTH SOLUTION

Emmaus Life Sciences, Inc. | April 12, 2022

news image

Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the launch of an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScriptHealth. The telehealth program capitalizes on the expansion of telemedicine in the U.S. to afford patients and providers on-line access to Endari®, the company's prescription-grade L-gl...

Read More

LYGENESIS ANNOUNCES FOUR PEER-REVIEWED PAPERS ARE PUBLISHED ON ITS ORGAN REGENERATION TECHNOLOGY

LyGenesis | August 28, 2020

news image

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using ...

Read More

INDUSTRIAL IMPACT

NOVALIQ SUBMITS NEW DRUG APPLICATION SEEKING APPROVAL FOR FIRST-OF-A-KIND DRY EYE DISEASE TREATMENT CYCLASOL®

Novaliq GmbH | August 10, 2022

news image

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for CyclASol® a proposed novel treatment for the signs and symptoms of dry eye disease. CyclASol® has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improveme...

Read More
news image

ENZO BIOCHEM’S FULL SERVICE CLINICAL LABORATORY TO LAUNCH CORONAVIRUS (COVID-19) TESTING SERVICES NEXT WEEK

Biotechnology news | March 06, 2020

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection...

Read More
news image

MEDICAL

EMMAUS LIFE SCIENCES ANNOUNCES LAUNCH OF FULL-SERVICE TELEHEALTH SOLUTION

Emmaus Life Sciences, Inc. | April 12, 2022

Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the launch of an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScriptHealth. The telehealth program capitalizes on the expansion of telemedicine in the U.S. to afford patients and providers on-line access to Endari®, the company's prescription-grade L-gl...

Read More
news image

LYGENESIS ANNOUNCES FOUR PEER-REVIEWED PAPERS ARE PUBLISHED ON ITS ORGAN REGENERATION TECHNOLOGY

LyGenesis | August 28, 2020

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using ...

Read More
news image

INDUSTRIAL IMPACT

NOVALIQ SUBMITS NEW DRUG APPLICATION SEEKING APPROVAL FOR FIRST-OF-A-KIND DRY EYE DISEASE TREATMENT CYCLASOL®

Novaliq GmbH | August 10, 2022

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for CyclASol® a proposed novel treatment for the signs and symptoms of dry eye disease. CyclASol® has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improveme...

Read More